Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (1) ·
Agomelatine (1) ·
Amantadine (1) ·
Amoxapine (1) ·
Apomorphine (1) ·
Benztropine (1) ·
Biperiden (1) ·
Bromocriptine (1) ·
Cabergoline (1) ·
Carbidopa/levodopa (1) ·
Clomipramine (1) ·
Desipramine (1) ·
Duloxetine (1) ·
Entacapone (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levodopa (1) ·
Levomilnacipran (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Nefazodone (1) ·
Opicapone (1) ·
Phenelzine (1) ·
Protriptyline (1) ·
Rasagiline (1) ·
Reboxetine (1) ·
Rotigotine (1) ·
Safinamide (1) ·
Selegiline (1) ·
Sertraline (1) ·
Tianeptine (1) ·
Tolcapone (1) ·
Tranylcypromine (1) ·
Trihexyphenidyl (1) ·
Trimipramine (1)
brand:
None (2) ·
Akineton (1) ·
Anafranil (1) ·
Apokyn (1) ·
Artane (1) ·
Aurorix (1) ·
Azilect (1) ·
Cogentin (1) ·
Comtan (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Dostinex (1) ·
Edronax (1) ·
Eldepryl (1) ·
Fetzima (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Neupro (1) ·
Norpramin (1) ·
Ongentys (1) ·
Parlodel (1) ·
Parnate (1) ·
Savella (1) ·
Serzone (1) ·
Sinemet (1) ·
Stablon (1) ·
Surmontil (1) ·
Symmetrel (1) ·
Tasmar (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Vraylar (1) ·
Xadago (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Central and peripheral COMT inhibitor (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Irreversible selective MAO-B inhibitor (2) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist; dopamine releasing agent (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Peripheral COMT inhibitor (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective M1 muscarinic antagonist (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (34) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1)
starting dose:
preparations:
onset:
duration:
halflife:
None (33) ·
Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) ·
~12 hours (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)
bioavailability:
pregnancy:
legal:
Showing below up to 36 results in range #1 to #36.